Key result
Aspirin and other antiplatelet agents, alone or in combination, were reviewed for their benefits and disadvantages in primary and secondary stroke prevention.
Why the study?
Clinical trials, guidelines, reviews, and expert opinions debate the optimal antiplatelet pharmacotherapy for primary and secondary stroke prevention.
Do antiplatelet drugs prevent cerebral ischemic events in patients requiring primary or secondary prevention?
Do antiplatelet drugs prevent cerebral ischemic events in patients requiring primary or secondary prevention?
This review summarizes the evidence on the benefits and risks of antiplatelet pharmacotherapy for primary and secondary stroke prevention.
May inform antiplatelet selection for stroke prevention; leaves open optimal regimen pending targeted RCTs.
Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the review were organized to show both benefits or consequences from antiplatelet pharmacotherapy. Conclusively, this review provides a potential synopsis on the most appropriate therapeutic approach for stroke prevention in clinical practice.
No takes yet. Share an insight, caveat, or question.
Signorelli et al. (2020) conducted a review in Stroke prevention. Antiplatelet drugs (Aspirin and others) was evaluated on Cerebral ischemic event (stroke, transient ischemic attack). Aspirin and other antiplatelet agents, alone or in combination, were reviewed for their benefits and disadvantages in primary and secondary stroke prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: